What You Should Know:
- Today, R&D Cloud pioneer Benchling announced it has acquired Overwatch Research to accelerate in vivo research.
- The acquisition will create the industry’s first comprehensive, cloud-native in vivo solution – a critical component of drug discovery and development – drastically accelerating the time it takes biopharma companies to bring products to market.
Digital Transforming R&D
In vivo studies are a critical component of drug discovery and
Read More
Benchling
Connecting the Dots – Building Data Bridges for a Better Healthcare Future
Healthcare data is increasing at an exponential rate. Approximately one-third of the world’s data volume is being generated by the healthcare industry. By 2025, the compound annual growth rate of healthcare data will reach 36% – that’s 6% faster than manufacturing, 10% faster than financial services, and 11% faster than media and entertainment.
In addition to information captured during visits with healthcare professionals, personal health information is being created by an increasingly
Read More
Biotech R&D Platform Benchling Closes $100M at $6B Valuation
What You Should Know:
Biotech R&D platform Benchling raises $100M at a $6B valuation, co-led by Franklin Templeton and Altimeter Capital to expand product development and global footprint, particularly in EMEA.
More than 200,000 scientists at over 600 companies and 7,000 research institutions globally have adopted Benchling's R&D Cloud to make breakthrough discoveries and bring the next generation of medicines, food, and materials to market faster than ever before. The R&D
Read More
Benchling Launches New RNA Capabilities to Accelerate Drug Discovery
What You Should Know:
- Benchling, the leading life sciences cloud, today announced the launch of RNA Therapeutics R&D, a new digital solution that allows scientists to design, analyze, and develop complex RNA therapeutics in a unified cloud platform for the first time.
- More than 1,000 R&D organizations/customers can now accelerate collaboration, speed, and simplicity for RNA research via Benchling — an important advance for biotech.
Biopharmaceutical R&D teams can
Read More
Led by Sequoia, Benchling Raises $200M to Accelerate R&D Cloud Platform
- Today Benchling, the leading life and sciences R&D cloud, announced a $200M Series E raise led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital, and Elad Gil. This funding will be used to aggressively invest in product development and global expansion to support enterprise customers. The raise is also joined by existing investors Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital, and Lead Edge Capital.
-
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry.
- The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients.
- A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
Benchling Launches New Products for Research & Biotech Startups to Accelerate Life Sciences Innovation
- Benchling launches two new products that will democratize access to industry-leading data management and collaboration software to the places they happen most: institutions and startup.- With Benchling, organizations from academic institutions, to startups, to major enterprises, can accelerate the pace at which they develop scientific breakthroughs, while minimizing time-consuming, antiquated processes. - The Benchling platform enables scientists to manage the complexity of biology research
Read More
Benchling Nabs $34.5M to Power Life Sciences R&D Cloud Platform
Benchling, a San
Francisco, CA-based life sciences R&D cloud platform announced it has raised
$34.5 million in Series C funding led by Menlo Ventures with new investors Lead
Edge Capital and Y Combinator Continuity as well as returning investors
Benchmark and Thrive Capital.
Replacing Outdated Pen and Paper Processes
Life science R&D has become incredibly complex -- from
the molecules to the processes to the multi-dimensional data. Until Benchling, there had been
Read More
Benchling Raises $14.5M for Biologics Platform to Streamline R&D for Scientists, Researchers
Benchling, a San Francisco, CA-based biologics platform for scientists, research managers, and executives to streamline and track R&D from discovery to bioprocessing, today announced it has raised $14.5M in Series B funding led by Benchmark. The round also included participation from from F-Prime Capital, a global venture capital firm associated with Fidelity Investments, and returning investor Thrive Capital. Benchling plans to utilize the funding to accelerate product development and
Read More
